BE900925A - Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci. - Google Patents

Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci.

Info

Publication number
BE900925A
BE900925A BE0/213911A BE213911A BE900925A BE 900925 A BE900925 A BE 900925A BE 0/213911 A BE0/213911 A BE 0/213911A BE 213911 A BE213911 A BE 213911A BE 900925 A BE900925 A BE 900925A
Authority
BE
Belgium
Prior art keywords
degrees
anhydrous
prazosin hydrochloride
crystalline form
micro
Prior art date
Application number
BE0/213911A
Other languages
English (en)
French (fr)
Inventor
S O E Lindholm
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of BE900925A publication Critical patent/BE900925A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BE0/213911A 1984-06-25 1984-10-29 Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci. BE900925A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI842544A FI79107C (fi) 1984-06-25 1984-06-25 Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Publications (1)

Publication Number Publication Date
BE900925A true BE900925A (fr) 1985-02-15

Family

ID=8519293

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/213911A BE900925A (fr) 1984-06-25 1984-10-29 Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci.

Country Status (17)

Country Link
US (2) US4739055A (online.php)
JP (1) JPS6115881A (online.php)
AT (1) AT389117B (online.php)
AU (1) AU566814B2 (online.php)
BE (1) BE900925A (online.php)
CH (1) CH661045A5 (online.php)
DE (1) DE3429415A1 (online.php)
FI (1) FI79107C (online.php)
FR (1) FR2567124B1 (online.php)
GB (1) GB2160861B (online.php)
IL (1) IL73267A (online.php)
IT (1) IT1224142B (online.php)
LU (1) LU85616A1 (online.php)
NL (1) NL8403250A (online.php)
NZ (1) NZ209962A (online.php)
PT (1) PT79411B (online.php)
ZA (1) ZA85910B (online.php)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816455A (en) * 1986-03-21 1989-03-28 Heumann Pharma Gmbh & Co. Crystalline, anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxy-quinazoline hydrochloride and a process for its preparation

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2756846B2 (ja) * 1989-12-28 1998-05-25 住化ファインケム株式会社 無水のε型結晶体２―〔４―（２―フロイル）ピペラジン―１―イル〕―４―アミノ―６，７―ジメトキシキナゾリン塩酸塩及びその製造方法
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE156532C (online.php) *
US2969375A (en) * 1961-01-24 Certification of correction
NL54420C (online.php) * 1937-05-25
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3433788A (en) * 1966-04-27 1969-03-18 Union Carbide Corp Process for recovery of amines from aqueous solutions by solvent treatment and distillation
US3421983A (en) * 1967-03-07 1969-01-14 Lummus Co Azeotropic distillation of aqueous toluene diamine
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3743672A (en) * 1970-05-27 1973-07-03 Halcon International Inc Separation of water in alkylene glycol mono and diester purification by azeotropic distillation
GB1308718A (en) * 1970-07-01 1973-03-07 Sir Soc Italiana Resine Spa Method of separating vinyl acetate from liquid mixtures
IT956765B (it) * 1972-06-22 1973-10-10 Montedison Spa Procedimento per la purificazione di 1 3 diossolano
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
FI64367C (fi) * 1980-02-26 1986-08-05 Orion Yhtymae Oy Foerfarande foer framstaellning av alfa-form av prazosinhydroklorid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816455A (en) * 1986-03-21 1989-03-28 Heumann Pharma Gmbh & Co. Crystalline, anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxy-quinazoline hydrochloride and a process for its preparation

Also Published As

Publication number Publication date
ZA85910B (en) 1985-09-25
JPH0481993B2 (online.php) 1992-12-25
GB2160861B (en) 1987-11-18
DE3429415C2 (online.php) 1990-05-03
GB2160861A (en) 1986-01-02
FI842544A0 (fi) 1984-06-25
FR2567124B1 (fr) 1990-09-21
CH661045A5 (de) 1987-06-30
PT79411B (en) 1986-09-15
IL73267A (en) 1988-06-30
FI79107C (fi) 1989-11-10
US4873330A (en) 1989-10-10
ATA344184A (de) 1989-03-15
AU566814B2 (en) 1987-10-29
NL8403250A (nl) 1986-01-16
FI79107B (fi) 1989-07-31
PT79411A (en) 1984-11-01
NZ209962A (en) 1987-06-30
JPS6115881A (ja) 1986-01-23
FR2567124A1 (fr) 1986-01-10
IT1224142B (it) 1990-09-26
GB8424999D0 (en) 1984-11-07
LU85616A1 (fr) 1985-06-04
AU3451084A (en) 1986-01-02
US4739055A (en) 1988-04-19
FI842544L (fi) 1985-12-26
IT8423292A0 (it) 1984-10-24
AT389117B (de) 1989-10-25
DE3429415A1 (de) 1986-01-02
IL73267A0 (en) 1985-01-31

Similar Documents

Publication Publication Date Title
HUT59376A (en) Process for producing r(+)-n-propargyl-1-aminoindane and pharmaceutical compositions comprising such compound
NO164537C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive r(+)- og s(-)-carbazolderivater, og r(-)- og s(+)-4-(2,3-epoxypropoxy)-carbazol for anvendelse ved fremgangsmaaten.
RU92016217A (ru) Двойные ингибиторы no синтазы и циклооксигеназы, способ их получения и фармацевтическая композиция на их основе
FR2567124B1 (fr) Nouvelle forme d cristalline, stable, anhydre du chlorhydrate de prazosine et nouveau procede pour la preparation de cette forme d cristalline
TNSN87015A1 (fr) Nouvelles n-heterocyclyl-4-piperidinamines, compositions contenant des n-heterocyclyl-4-piperidinamines, procede de traitement les utilisant et procede pour preparer des n-heterocyclyl-4- piperidinamines
RU92016444A (ru) Получение производных пиперидинов и производных пиперидина
HUT68166A (en) Process for preparing substituted piperidines
EA200100533A1 (ru) Производные эритромицина, способ их получения и их применение в качестве лекарственных средств
IT8023576A0 (it) Processo per la produzione dicomposti di titanio.
NO941958D0 (no) Fremstilling av substituerte piperidiner
ITMI20022076A1 (it) Sali di intermedi del cefdinir.
MA19948A1 (fr) Procede de preparation de derives de la piperidine-dione protecteur du myocarde presentant une activite antiarithmique
Prugh et al. Methyl 3-0-benzyl-2, 4, 6-trideoxy-6-iodo-α-d-erythro-hexopyranoside, a chiral synthon for the synthesis of inhibitors of HMG-CoA reductase
DK326481A (da) Fremgangsmaade til fremstilling af i 5-stillingen substituerede 5,10-dihydro-11h-dibenzo (b,e) (1,4) diazepin-11-oner eller syreadditionssalte deraf
ES8706598A1 (es) Un procedimiento para preparar nuevos derivados de aminocetona
MD970135A (en) Arylthiocompound as an antibacterial and antiviral remedy
HUT39147A (en) Process for preparing phenoxy-propanol-acethylene derivatives and pharmaceutical compositions containing such compounds
EA199900156A1 (ru) Новые производные эритромицина, способ их получения и их применение в качестве медикаментов
IT1112971B (it) Processo per la sintesi di alcossialanati di metalli alcalino-terrosi
Lundkvist et al. Facile synthesis of resolved α-ethynyl-substituted cyclic amines
FI834174A0 (fi) Nya benzazepinderivater, deras framstaellning och deras anvaendning saosom laekemedel
SE8801798L (sv) Chemical intermediates and process
DK104388D0 (da) Hidtil ukendte 2-(2,3-dihydro-2-oxo-3-benzofuranyl)-eddikesyrederivater, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem
IT7928251A0 (it) Processo per la sintesi di 4-[2-(dimetilammino)-etossi]2-metil-5-81-metiletil)-fenol-este ri
McCord et al. Diastereomers of 2-amino-3-methylaminobutyric acid, aza analogs of isoleucine

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: ORION-YHTYMA OY FERMION

Effective date: 19951031